<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Peptic ulcer disease: Treatment and secondary prevention
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Peptic ulcer disease: Treatment and secondary prevention
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Peptic ulcer disease: Treatment and secondary prevention
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nimish B Vakil, MD, AGAF, FACP, FACG, FASGE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark Feldman, MD, MACP, AGAF, FACG
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 08, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         A peptic ulcer is a defect in the gastric or duodenal wall that extends through the muscularis mucosa into the deeper layers of the wall. The management of patients with peptic ulcer disease is based on the etiology, ulcer characteristics, and anticipated natural history. This topic will review the initial management of peptic ulcer disease. The management of recurrent peptic ulcer disease, the complications of peptic ulcer disease, surgical management of peptic ulcer disease, and the clinical manifestations and diagnosis of peptic ulcer disease are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/27.html" rel="external">
          "Approach to refractory peptic ulcer disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/24.html" rel="external">
          "Overview of complications of peptic ulcer disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8040.html" rel="external">
          "Surgical management of peptic ulcer disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/26.html" rel="external">
          "Peptic ulcer disease: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H434386266">
         <span class="h1">
          INITIAL MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2932995151">
         <span class="h2">
          Treat the underlying etiology
         </span>
        </p>
        <p class="headingAnchor" id="H527229648">
         <span class="h3">
          Eradication of Helicobacter pylori (H. pylori)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with peptic ulcers should be tested for infection with
         <em>
          H. pylori
         </em>
         and treated accordingly  (
         <a class="graphic graphic_algorithm graphicRef126285" data-inline-graphics="126285" href="/z/d/graphic/126285.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1-4
         </a>
         ]. Eradication of
         <em>
          H. pylori
         </em>
         in patients with peptic ulcer disease is associated with higher healing rates in patients with duodenal and gastric ulcers. A meta-analysis of 24 randomized trials that included 2102 patients with peptic ulcer disease revealed that the 12-month ulcer remission rates for gastric and duodenal ulcers were significantly higher in patients successfully eradicated of
         <em>
          H. pylori
         </em>
         infection as compared with those with a persistent infection (97 and 98 percent versus 61 and 65 percent, respectively) [
         <a href="#rid5">
          5
         </a>
         ]. In addition, eradication of
         <em>
          H. pylori
         </em>
         infection is associated with lower ulcer recurrence rates in patients with gastric and duodenal ulcers who are not placed on maintenance antisecretory therapy [
         <a href="#rid6">
          6
         </a>
         ]. Treatment regimens for
         <em>
          H. pylori
         </em>
         are discussed in detail, separately. (See
         <a class="medical medical_review" href="/z/d/html/18.html" rel="external">
          "Indications and diagnostic tests for Helicobacter pylori infection in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7.html" rel="external">
          "Treatment regimens for Helicobacter pylori in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H368389732">
         <span class="h3">
          Discontinue nonsteroidal anti-inflammatory drugs (NSAIDs)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with peptic ulcers should be advised to avoid NSAIDs. NSAIDs, including
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , increase the risk of peptic ulcer disease and are associated with an increased risk of complications from a peptic ulcer.
        </p>
        <p class="headingAnchor" id="H2972307099">
         <span class="h3">
          Rare or unclear cause
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rare causes of ulcer disease (eg, infections, Crohn disease, ischemia) should be addressed and treated. In patients with peptic ulcer disease of unclear etiology, additional evaluation is needed to exclude other rare causes of peptic ulcer disease (see
         <a class="medical medical_review" href="/z/d/html/23.html" rel="external">
          "Unusual causes of peptic ulcer disease"
         </a>
         ). Gastrointestinal bleeding is a complication of severe coronavirus infections and peptic ulcer disease is the most common cause. In one study of consecutive patients in Northern Italy, the prevalence was 0.5 percent and the mortality rate was 21 percent, primarily due to pulmonary complications [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Initial antisecretory therapy
         </span>
        </p>
        <p class="headingAnchor" id="H368390202">
         <span class="h3">
          Choice of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with peptic ulcers should receive antisecretory therapy with a proton pump inhibitor (PPI; eg,
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         20 to 40 mg daily or equivalent) to facilitate ulcer healing  (
         <a class="graphic graphic_algorithm graphicRef126285" href="/z/d/graphic/126285.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_table graphicRef81079" href="/z/d/graphic/81079.html" rel="external">
          table 1
         </a>
         ). PPI use results in faster control of peptic ulcer disease symptoms and higher ulcer healing rates as compared with H2RA as a consequence of stronger acid suppression. PPIs also heal NSAID-related ulcers more effectively as compared with H2RAs [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/32.html" rel="external">
          "Antiulcer medications: Mechanism of action, pharmacology, and side effects", section on 'Indications and comparative efficacy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Pharmacology'
         </a>
         .)
        </p>
        <p>
         Combining PPIs and H2RAs adds to cost without enhancing healing. Although antacids and
         <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">
          sucralfate
         </a>
         can heal duodenal ulcers, they are not routinely recommended to treat peptic ulcers as PPIs heal ulcers more rapidly and to a greater extent.
        </p>
        <p class="headingAnchor" id="H874126041">
         <span class="h3">
          Duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The duration of initial antisecretory therapy varies based on the ulcer characteristics, the underlying etiology (
         <em>
          H. pylori
         </em>
         , NSAID use) and the presence of ulcer complications (eg, bleeding, perforation, penetration, or gastric outlet obstruction) [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/24.html" rel="external">
          "Overview of complications of peptic ulcer disease"
         </a>
         and
         <a class="local">
          'Prevention of recurrence'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H236985435">
         <span class="h4">
          Complicated ulcer
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with complicated peptic ulcers (ulcers with bleeding, perforation, penetration, or gastric outlet obstruction) should initially receive high-dose acid suppressive therapy. The treatment of bleeding peptic ulcers is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">
          "Approach to acute upper gastrointestinal bleeding in adults", section on 'Acid suppression'
         </a>
         .)
        </p>
        <p>
         In patients with peptic-ulcer-related complications
         <strong>
          other than bleeding
         </strong>
         (gastric outlet obstruction, penetration, perforation), high-dose twice-daily PPI treatment is reasonable to enhance healing (eg, oral
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         40 mg twice daily), but dosing should generally be reduced to once daily after four weeks. In patients with complicated duodenal ulcers, we suggest antisecretory treatment for four to eight weeks. In patients with complicated gastric ulcers, we suggest antisecretory therapy for a total duration of 8 to 12 weeks. In patients with gastric ulcers, we discontinue antisecretory therapy only after ulcer healing has been confirmed by upper endoscopy. (See
         <a class="medical medical_review" href="/z/d/html/24.html" rel="external">
          "Overview of complications of peptic ulcer disease", section on 'Acid suppressive therapy'
         </a>
         and
         <a class="local">
          'Gastric ulcers'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2928983088">
         <span class="h4">
          Uncomplicated ulcer
         </span>
        </p>
        <p class="headingAnchor" id="H1201047157">
         <span class="h4">
          H. pylori-positive ulcer
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with uncomplicated ulcers, PPI (eg,
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         20 mg twice daily) given for 14 days, along with the antibiotic regimen to treat
         <em>
          H. pylori
         </em>
         , is usually adequate to induce healing. Additional antisecretory therapy is not needed in the absence of persistent or recurrent symptoms following therapy or other indications for maintenance antisecretory therapy [
         <a href="#rid10">
          10,11
         </a>
         ]. Eradication
         <em>
          of H. pylori
         </em>
         even without concurrent acid suppression therapy heals &gt;90 percent of duodenal ulcers [
         <a href="#rid12">
          12,13
         </a>
         ]. (See
         <a class="local">
          'Prevention of recurrence'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H903407570">
         <span class="h4">
          NSAID-induced ulcer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with NSAID-associated ulcers should be treated with a PPI (eg,
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         20 to 40 mg daily) for four to eight to weeks based on the size of the ulcer  (
         <a class="graphic graphic_table graphicRef81079" href="/z/d/graphic/81079.html" rel="external">
          table 1
         </a>
         ). In patients with peptic ulcers who need to remain on NSAIDs or
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , maintenance antisecretory therapy with a PPI (eg, omeprazole 20 mg daily) can reduce the risk of ulcer complications or recurrence [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="local">
          'Prevention of recurrence'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/14.html" rel="external">
          "NSAIDs (including aspirin): Treatment and secondary prevention of gastroduodenal toxicity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3654464114">
         <span class="h4">
          Non-H. pylori, non-NSAID ulcer
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with
         <em>
          H. pylori
         </em>
         -negative ulcers that are not associated with NSAID use, we suggest initial PPI therapy for four weeks for uncomplicated duodenal ulcers, and eight weeks for a gastric ulcer or any complicated ulcer before repeat endoscopic evaluation to assess for ulcer healing. Although the natural history of these ulcers is unclear, it is important to review the patient's history for the adequacy of
         <em>
          H. pylori
         </em>
         testing and for a history of NSAID use. Limited data on the natural history of these ulcers suggest that they may be more difficult to heal and have a higher rate of recurrence. In the absence of
         <em>
          H. pylori
         </em>
         and NSAID use, we continue long-term acid inhibitory therapy with PPIs [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="local">
          'Prevention of recurrence'
         </a>
         below and
         <a class="local">
          'Repeat upper endoscopy in selected patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3581850050">
         <span class="h2">
          Other general measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Underlying risk factors for peptic ulcer disease should be addressed and treated. Given the many benefits of smoking cessation, we advise patients to stop smoking and advise them to limit alcohol intake to one alcoholic beverage a day [
         <a href="#rid16">
          16
         </a>
         ]. Evidence to support the use of a bland diet or dietary restrictions in patients with peptic ulcer disease is lacking. (See
         <a class="medical medical_review" href="/z/d/html/22.html" rel="external">
          "Peptic ulcer disease: Epidemiology, etiology, and pathogenesis", section on 'Risk factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2029912476">
         <span class="h1">
          SUBSEQUENT MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Repeat upper endoscopy in selected patients
         </span>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Duodenal ulcers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the low risk of malignancy in patients with duodenal ulcers, a repeat upper endoscopy is not routinely recommended, but may be performed in selected patients four weeks after initial treatment unless symptoms persist or recur  (
         <a class="graphic graphic_algorithm graphicRef126285" href="/z/d/graphic/126285.html" rel="external">
          algorithm 1
         </a>
         ). Endoscopy should be repeated in patients with signs of ongoing bleeding [
         <a href="#rid17">
          17
         </a>
         ]. The decision to perform a repeat upper endoscopy in patients with duodenal ulcers of unclear etiology should be individualized. (See
         <a class="medical medical_review" href="/z/d/html/23.html" rel="external">
          "Unusual causes of peptic ulcer disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Gastric ulcers
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest a surveillance endoscopy (with biopsies of the ulcer if still present) be performed after 8 to 12 weeks in patients with gastric ulcers and any one of the following  (
         <a class="graphic graphic_algorithm graphicRef126285" href="/z/d/graphic/126285.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms persist despite medical therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unclear etiology.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Giant ulcer (&gt;2 cm).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biopsies not performed or inadequate sampling on the index upper endoscopy. To adequately sample a gastric ulcer, we suggest a minimum of four biopsies should be obtained, with at least one from each of the four quadrants of the ulcer. Additional biopsies of the edges should be taken with jumbo forceps if there are endoscopic features of a malignant gastric ulcer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ulcer appears suspicious for malignancy on index upper endoscopy (mass lesion, elevated irregular ulcer borders, or abnormal adjacent mucosal folds). Surveillance endoscopy should be considered in patients whose gastric ulcer appears endoscopically suspicious for malignancy, even if biopsy samples from the index endoscopy are benign. False-negative biopsy specimen results have been reported to occur in 2 percent to 5 percent of malignant ulcers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with bleeding ulcers at initial presentation who show signs of continued bleeding [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Risks factors for gastric cancer (eg, age &gt;50 years
         <em>
          , Helicobacter pylori
         </em>
         , immigrants from a region with high prevalence of gastric cancer [eg, Japan, Korea, Taiwan, Costa Rica], family history of gastric cancer, the presence of gastric atrophy, adenoma, dysplasia, intestinal metaplasi
         <em>
          a
         </em>
         ).
        </p>
        <p>
        </p>
        <p>
         Our approach is not to perform an upper endoscopy for surveillance in patients with small benign-appearing antral gastric ulcers due to nonsteroidal anti-inflammatory drug use that have been adequately biopsied and have no evidence of dysplasia or malignancy if the patient has no risk factors for gastric cancer [
         <a href="#rid18">
          18-20
         </a>
         ].
        </p>
        <p>
         There are limited prospective outcome data to guide which patients with peptic ulcers should undergo surveillance endoscopy. Our recommendations are consistent with the 2010 guidelines by the American Society for Gastrointestinal Endoscopy [
         <a href="#rid17">
          17
         </a>
         ]. The incidence of gastric cancer on follow-up endoscopy of an apparently benign gastric ulcer ranges from 0.8 to 4.3 percent. The rationale behind endoscopic follow-up of a patient with a gastric ulcer is that the absence of symptoms does not reliably exclude malignancy, and surveillance endoscopy may identify patients with gastric cancer at an early stage [
         <a href="#rid21">
          21,22
         </a>
         ]. However, it is unclear if endoscopic surveillance is cost-effective or improves survival [
         <a href="#rid21">
          21,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3433455217">
         <span class="h2">
          Refractory ulcers
         </span>
         <span class="headingEndMark">
          —
         </span>
         A refractory peptic ulcer is defined as an endoscopically proven ulcer greater than 5 mm in diameter that does not heal after 8 to 12 weeks of treatment with a proton pump inhibitor (PPI). Approximately 5 to 10 percent of ulcers are refractory to initial PPI therapy. The evaluation and management of refractory ulcers is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/27.html" rel="external">
          "Approach to refractory peptic ulcer disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1593274572">
         <span class="h1">
          PREVENTION OF RECURRENCE
         </span>
        </p>
        <p class="headingAnchor" id="H56286521">
         <span class="h2">
          Aspirin/nonsteroidal anti-inflammatory drug (NSAID) avoidance
         </span>
         <span class="headingEndMark">
          —
         </span>
         The need for
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and NSAIDs should be carefully assessed in patients with a history of peptic ulcer disease. NSAIDs, including aspirin, increase the risk of bleeding in patients with prior peptic ulcer disease. For patients who must continue aspirin or NSAIDs, or both, we recommend treatment with a proton pump inhibitor (PPI) for as long as the NSAID and/or aspirin is used. This is particularly important in patients who need continued NSAIDs and have additional risk factors for gastroduodenal toxicity (age &gt;65 years, complicated peptic ulcer disease, high-dose NSAID use, NSAID use with other medications associated with peptic ulcer disease [eg, SSRIs, low-dose aspirin]). (See
         <a class="medical medical_review" href="/z/d/html/14.html" rel="external">
          "NSAIDs (including aspirin): Treatment and secondary prevention of gastroduodenal toxicity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3247431733">
         <span class="h2">
          H. pylori eradication
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition,
         <em>
          H. pylori
         </em>
         infection should be eradicated, if known to be present. For patients with
         <em>
          H. pylori
         </em>
         infection who cannot discontinue NSAIDs, rebleeding rates are reduced with eradication of
         <em>
          H. pylori
         </em>
         infection in combination with long-term PPI therapy. (See
         <a class="medical medical_review" href="/z/d/html/18.html" rel="external">
          "Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Confirm eradication in all patients'
         </a>
         .)
        </p>
        <p>
         In patients treated for
         <em>
          H. pylori,
         </em>
         eradication of infection should be confirmed four or more weeks after the completion of therapy [
         <a href="#rid4">
          4
         </a>
         ]. The choice of test depends on the need for an upper endoscopy (eg, follow-up of bleeding peptic ulcer). (See
         <a class="local">
          'Repeat upper endoscopy in selected patients'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/18.html" rel="external">
          "Indications and diagnostic tests for Helicobacter pylori infection in adults"
         </a>
         .)
        </p>
        <p>
         PPIs should be held for one to two weeks prior to testing to reduce false-negative results. Serologic testing should not be performed to confirm eradication as patients may continue to have antibodies after eradication. Diagnostic evaluation and treatment of
         <em>
          H. pylori
         </em>
         are discussed in detail, separately. (See
         <a class="medical medical_review" href="/z/d/html/18.html" rel="external">
          "Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Medications that should be discontinued prior to testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2613317508">
         <span class="h2">
          Maintenance antisecretory therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision to continue maintenance antisecretory therapy varies based on the patient and ulcer characteristics and risk factors for recurrent peptic ulcer disease [
         <a href="#rid9">
          9
         </a>
         ]. While PPIs, H2 receptor antagonists, and prostaglandin analogs have been used as maintenance therapy to prevent recurrent ulcers, PPIs are the most effective agents in preventing recurrent ulcers and recurrent ulcer bleeding [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         We continue maintenance antisecretory therapy with a PPI (eg,
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         20 mg daily) in the following patients with peptic ulcer disease  (
         <a class="graphic graphic_table graphicRef81079" href="/z/d/graphic/81079.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid25">
          25-31
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Giant (&gt;2 cm) peptic ulcer and age &gt;50 years or multiple co-morbidities
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          H. pylori
         </em>
         -negative, NSAID-negative ulcer disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Failure to eradicate
         <em>
          H. pylori
         </em>
         (including salvage therapy)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Frequently recurrent peptic ulcers (&gt;2 documented recurrences a year)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Continued NSAID use
        </p>
        <p>
        </p>
        <p>
         The prevention of recurrent gastroduodenal toxicity associated with NSAID, low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or both therapies (secondary prevention) is discussed in detail, separately. (See
         <a class="medical medical_review" href="/z/d/html/2573.html" rel="external">
          "Overview of the treatment of bleeding peptic ulcers", section on 'Resumption of anticoagulants and antiplatelet agents'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14.html" rel="external">
          "NSAIDs (including aspirin): Treatment and secondary prevention of gastroduodenal toxicity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H60746972">
         <span class="h1">
          TREATMENT DURING PREGNANCY AND LACTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         When peptic ulcer disease is diagnosed in a woman who is pregnant, the focus of treatment is typically acid suppression with a proton pump inhibitor (PPI) [
         <a href="#rid32">
          32
         </a>
         ]. If
         <em>
          Helicobacter pylori
         </em>
         (
         <em>
          H. pylori
         </em>
         ) is present, antimicrobial treatment is typically deferred until after delivery. However, there is some evidence that
         <em>
          H. pylori
         </em>
         can cause severe nausea/vomiting in pregnancy, including hyperemesis gravidarum [
         <a href="#rid33">
          33,34
         </a>
         ]. Thus, if indicated,
         <em>
          H. pylori
         </em>
         treatment can be considered in pregnancy. A meta-analysis of safety studies showed no significant adverse outcomes with PPI use in pregnant women [
         <a href="#rid35">
          35-37
         </a>
         ]. The available evidence based on clinical studies in pregnancy supports the safety of older proton pump inhibitors such as
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9474" href="/z/d/drug information/9474.html" rel="external">
          pantoprazole
         </a>
         with little data available on the newer proton pump inhibitors. Similarly, limited data with omeprazole and pantoprazole suggest that excretion in breast milk does occur but the levels are low [
         <a href="#rid38">
          38-40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults", section on 'Pregnancy and lactation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112420.html" rel="external">
          "Prenatal care: Patient education, health promotion, and safety of commonly used drugs", section on 'Antibiotics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H434385486">
         <span class="h1">
          DISEASE COURSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 60 percent of peptic ulcers heal spontaneously but with eradication of
         <em>
          Helicobacter pylori
         </em>
         (
         <em>
          H. pylori
         </em>
         ) infection, ulcer healing rates are &gt;90 percent [
         <a href="#rid5">
          5,41-44
         </a>
         ]. Approximately 5 to 10 percent of ulcers are refractory to antisecretory therapy with a proton pump inhibitor (PPI). The risk of complications in patients with chronic peptic ulcer disease is 2 to 3 percent per year. (See
         <a class="medical medical_review" href="/z/d/html/27.html" rel="external">
          "Approach to refractory peptic ulcer disease"
         </a>
         .)
        </p>
        <p>
         Even with continued PPI use, approximately 5 to 30 percent of peptic ulcers recur within the first year based on whether
         <em>
          H. pylori
         </em>
         has been successfully eradicated [
         <a href="#rid45">
          45,46
         </a>
         ]. Recurrent ulcers are usually due to
         <em>
          H. pylori
         </em>
         infection or nonsteroidal anti-inflammatory drug use but in rare cases may be due to other etiologies  (
         <a class="graphic graphic_table graphicRef101181" data-inline-graphics="101181" href="/z/d/graphic/101181.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1049035114">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117855.html" rel="external">
          "Society guideline links: Peptic ulcer disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H91474540">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15735.html" rel="external">
          "Patient education: Peptic ulcers (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15734.html" rel="external">
          "Patient education: H. pylori infection (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16944.html" rel="external">
          "Patient education: Gastritis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/2016.html" rel="external">
          "Patient education: Peptic ulcer disease (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/2012.html" rel="external">
          "Patient education: Helicobacter pylori infection and treatment (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of the underlying etiology
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with peptic ulcer disease should be tested for
         <em>
          Helicobacter pylori
         </em>
         (
         <em>
          H. pylori
         </em>
         ). Patients with
         <em>
          H. pylori
         </em>
         should be treated with a goal of eradication of
         <em>
          H. pylori
         </em>
         infection. In patients treated for
         <em>
          H. pylori,
         </em>
         eradication of infection should be confirmed four or more weeks after the completion of eradication therapy. (See
         <a class="medical medical_review" href="/z/d/html/18.html" rel="external">
          "Indications and diagnostic tests for Helicobacter pylori infection in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with peptic ulcers should be advised to avoid nonsteroidal anti-inflammatory drugs (NSAIDs). Contributing factors should be addressed and treated (eg, treating medical comorbidities, poor nutritional status, ischemia). (See
         <a class="local">
          'Rare or unclear cause'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/23.html" rel="external">
          "Unusual causes of peptic ulcer disease", section on 'Etiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/23.html" rel="external">
          "Unusual causes of peptic ulcer disease", section on 'Evaluation of H. pylori and NSAID negative ulcers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antisecretory therapy
         </strong>
         – All patients with peptic ulcer disease should receive antisecretory therapy with a proton pump inhibitor (PPI) to facilitate ulcer healing  (
         <a class="graphic graphic_algorithm graphicRef126285" href="/z/d/graphic/126285.html" rel="external">
          algorithm 1
         </a>
         ). The choice and duration of therapy varies based on the etiology, ulcer location (eg, gastric or duodenal), and the presence of ulcer complications (eg, bleeding, perforation, penetration, or gastric outlet obstruction). (See
         <a class="local">
          'Initial antisecretory therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for surveillance endoscopy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with duodenal ulcers who have been treated do not need further endoscopy unless symptoms persist at four weeks or recur. (See
         <a class="local">
          'Duodenal ulcers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with gastric ulcers, the decision to perform surveillance endoscopy should be individualized. We suggest surveillance endoscopy (with biopsies of the ulcer if still present) be performed after 8 to 12 weeks of antisecretory therapy in patients with gastric ulcers and any one of the following (see
         <a class="local">
          'Repeat upper endoscopy in selected patients'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Symptoms despite medical therapy
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Unclear etiology
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Giant gastric ulcer (&gt;2 cm)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Biopsies not performed or inadequate sampling on the index upper endoscopy
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Ulcer appears suspicious for malignancy on index upper endoscopy (mass lesion, elevated irregular ulcer borders, or abnormal adjacent mucosal folds)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients with bleeding ulcers at initial presentation who show signs of continued bleeding
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Risks factors for gastric cancer
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of recurrence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The need for
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and NSAIDs should be carefully assessed in patients with a history of peptic ulcer disease. NSAIDs, including aspirin, increase the risk of bleeding in patients with prior peptic ulcer disease. In patients treated for
         <em>
          H. pylori,
         </em>
         eradication of infection should be confirmed four or more weeks after the completion of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Maintenance antisecretory therapy should be limited to high-risk subgroups of patients with peptic ulcer disease. These include individuals with any one of the following (see
         <a class="local">
          'Prevention of recurrence'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Refractory peptic ulcer
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <em>
          H. pylori
         </em>
         -negative, NSAID-negative ulcer disease
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Giant (&gt;2 cm) ulcer and age &gt;50 years or multiple comorbidities
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Failure of
         <em>
          H. pylori
         </em>
         eradication, including rescue therapies
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Frequently recurrent peptic ulcers (&gt;2 documented recurrences a year)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Continued NSAID use
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease course
         </strong>
         – Approximately 60 percent of peptic ulcers heal spontaneously but with eradication of
         <em>
          H. pylori
         </em>
         infection, ulcer healing rates are &gt;90 percent. Even with continued proton pump inhibitor (PPI) use, approximately 5 to 30 percent of peptic ulcers recur within the first year based on whether
         <em>
          H. pylori
         </em>
         has been successfully eradicated. Approximately 5 to 10 percent of ulcers are refractory to antisecretory therapy with a PPI. The risk of complications in patients with chronic peptic ulcer disease is 2 to 3 percent per year. (See
         <a class="local">
          'Disease course'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/27.html" rel="external">
          "Approach to refractory peptic ulcer disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/24.html" rel="external">
          "Overview of complications of peptic ulcer disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1268337912">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Andrew H. Soll, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994; 272:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2:1437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiorean MV, Locke GR 3rd, Zinsmeister AR, et al. Changing rates of Helicobacter pylori testing and treatment in patients with peptic ulcer disease. Am J Gastroenterol 2002; 97:3015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leodolter A, Kulig M, Brasch H, et al. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001; 15:1949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004; 99:1833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mauro A, De Grazia F, Lenti MV, et al. Upper gastrointestinal bleeding in COVID-19 inpatients: Incidence and management in a multicenter experience from Northern Italy. Clin Res Hepatol Gastroenterol 2021; 45:101521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeomans ND, Tulassay Z, Juhász L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gudmand-Høyer E, Jensen KB, Krag E, et al. Prophylactic effect of cimetidine in duodenal ulcer disease. Br Med J 1978; 1:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther 2005; 21:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam SK, Ching CK, Lai KC, et al. Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study. Gut 1997; 41:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sung JJ, Chung SC, Ling TK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995; 332:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346:2033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung CS, Chiang TH, Lee YC. A systematic approach for the diagnosis and treatment of idiopathic peptic ulcers. Korean J Intern Med 2015; 30:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li LF, Chan RL, Lu L, et al. Cigarette smoking and gastrointestinal diseases: the causal relationship and underlying molecular mechanisms (review). Int J Mol Med 2014; 34:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ASGE Standards of Practice Committee, Banerjee S, Cash BD, et al. The role of endoscopy in the management of patients with peptic ulcer disease. Gastrointest Endosc 2010; 71:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosokawa O, Watanabe K, Hatorri M, et al. Detection of gastric cancer by repeat endoscopy within a short time after negative examination. Endoscopy 2001; 33:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whiting JL, Sigurdsson A, Rowlands DC, et al. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 2002; 50:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gielisse EA, Kuyvenhoven JP. Follow-up endoscopy for benign-appearing gastric ulcers has no additive value in detecting malignancy: It is time to individualise surveillance endoscopy. Gastric Cancer 2015; 18:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eckardt VF, Giessler W, Kanzler G, Bernhard G. Does endoscopic follow-up improve the outcome of patients with benign gastric ulcers and gastric cancer? Cancer 1992; 69:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stephens MR, Lewis WG, White S, et al. Prognostic significance of alarm symptoms in patients with gastric cancer. Br J Surg 2005; 92:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bytzer P. Endoscopic follow-up study of gastric ulcer to detect malignancy: is it worthwhile? Scand J Gastroenterol 1991; 26:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018; 3:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gisbert JP, Khorrami S, Carballo F, et al. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004; 19:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dammann HG, Walter TA. Efficacy of continuous therapy for peptic ulcer in controlled clinical trials. Aliment Pharmacol Ther 1993; 7 Suppl 2:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bianchi Porro G, Parente F. Long term treatment of duodenal ulcer. A review of management options. Drugs 1991; 41:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauritsen K, Andersen BN, Laursen LS, et al. Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial. Gastroenterology 1991; 100:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penston JG, Wormsley KG. Review article: maintenance treatment with H2-receptor antagonists for peptic ulcer disease. Aliment Pharmacol Ther 1992; 6:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penston JG. A decade of experience with long-term continuous treatment of peptic ulcers with H2-receptor antagonists. Aliment Pharmacol Ther 1993; 7 Suppl 2:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sverdén E, Agréus L, Dunn JM, Lagergren J. Peptic ulcer disease. BMJ 2019; 367:l5495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006; 131:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li L, Li L, Zhou X, et al. Helicobacter pylori Infection Is Associated with an Increased Risk of Hyperemesis Gravidarum: A Meta-Analysis. Gastroenterol Res Pract 2015; 2015:278905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grooten IJ, Den Hollander WJ, Roseboom TJ, et al. Helicobacter pylori infection: a predictor of vomiting severity in pregnancy and adverse birth outcome. Am J Obstet Gynecol 2017; 216:512.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill SK, O'Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009; 104:1541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med 2010; 363:2114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matok I, Levy A, Wiznitzer A, et al. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci 2012; 57:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall JK, Thompson AB, Armstrong D. Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. Can J Gastroenterol 1998; 12:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plante L, Ferron GM, Unruh M, Mayer PR. Excretion of pantoprazole in human breast. J Reprod Med 2004; 49:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nava-Ocampo AA, Velázquez-Armenta EY, Han JY, Koren G. Use of proton pump inhibitors during pregnancy and breastfeeding. Can Fam Physician 2006; 52:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jorde R, Bostad L, Burhol PG. Asymptomatic gastric ulcer: a follow-up study in patients with previous gastric ulcer disease. Lancet 1986; 1:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther 1990; 4:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaneko E, Ooi S, Ito G, Honda N. Natural history of duodenal ulcer detected by the gastric mass surveys in men over 40 years of age. Scand J Gastroenterol 1989; 24:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110:1244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998; 93:1409.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 25 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8007082" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2904568" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12492184" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Changing rates of Helicobacter pylori testing and treatment in patients with peptic ulcer disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27707777" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11736726" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15330927" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32888875" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Upper gastrointestinal bleeding in COVID-19 inpatients: Incidence and management in a multicenter experience from Northern Italy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9494148" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22491499" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/346161" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prophylactic effect of cimetidine in duodenal ulcer disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15801914" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9274470" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7800005" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12087138" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26354049" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A systematic approach for the diagnosis and treatment of idiopathic peptic ulcers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24859303" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Cigarette smoking and gastrointestinal diseases: the causal relationship and underlying molecular mechanisms (review).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20363407" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The role of endoscopy in the management of patients with peptic ulcer disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11315889" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Detection of gastric cancer by repeat endoscopy within a short time after negative examination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11839718" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The long term results of endoscopic surveillance of premalignant gastric lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25312052" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Follow-up endoscopy for benign-appearing gastric ulcers has no additive value in detecting malignancy: It is time to individualise surveillance endoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1728360" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Does endoscopic follow-up improve the outcome of patients with benign gastric ulcers and gastric cancer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15892157" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Prognostic significance of alarm symptoms in patients with gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1754856" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Endoscopic follow-up study of gastric ulcer to detect malignancy: is it worthwhile?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29475806" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15023164" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8364140" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Efficacy of continuous therapy for peptic ulcer in controlled clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1706986" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Long term treatment of duodenal ulcer. A review of management options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1993488" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1347467" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Review article: maintenance treatment with H2-receptor antagonists for peptic ulcer disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8103373" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A decade of experience with long-term continuous treatment of peptic ulcers with H2-receptor antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31578179" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Peptic ulcer disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16831611" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25861257" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Helicobacter pylori Infection Is Associated with an Increased Risk of Hyperemesis Gravidarum: A Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28188774" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Helicobacter pylori infection: a predictor of vomiting severity in pregnancy and adverse birth outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19491869" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21105793" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Use of proton-pump inhibitors in early pregnancy and the risk of birth defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22038541" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The safety of fetal exposure to proton-pump inhibitors during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9582548" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15568407" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Excretion of pantoprazole in human breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16893146" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Use of proton pump inhibitors during pregnancy and breastfeeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2867346" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Asymptomatic gastric ulcer: a follow-up study in patients with previous gastric ulcer disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2151756" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The relationship between suppression of acidity and gastric ulcer healing rates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2142113" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2928732" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Natural history of duodenal ulcer detected by the gastric mass surveys in men over 40 years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8613015" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9732917" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
